Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Adenocarcinoma × olaparib × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Ovarian Neoplasms 34 Breast Neoplasms 26 Triple Negative Breast Neoplasms 17 Prostatic Neoplasms 17 Fallopian Tube Neoplasms 11 Neoplasms 9 Pancreatic Neoplasms 7 Fanconi Anemia, Complementation Group D1 7 Endometrial Neoplasms 7 Glioma 6 Carcinoma, Ovarian Epithelial 6 Stomach Neoplasms 5 Small Cell Lung Carcinoma 5 Sarcoma 5 Neoplasm Metastasis 5 Cholangiocarcinoma 5 Uterine Cervical Neoplasms 4 Urinary Bladder Neoplasms 4 Lymphoma, Non-Hodgkin 4 Carcinoma, Non-Small-Cell Lung 4 Advanced Breast Cancer 4 Squamous Cell Carcinoma of Head and Neck 3 Recurrence 3 Osteosarcoma 3 Lung Neoplasms 3 Glioblastoma 3 Colorectal Neoplasms 3 Carcinosarcoma 3 Carcinoma, Renal Cell 3 Wilms Tumor 2

Interventions

Oxaliplatin 26 Gemcitabine 22 Fluorouracil 17 Capecitabine 16 Leucovorin 15 pembrolizumab 14 Docetaxel 14 Cisplatin 13 Bevacizumab 12 Radiotherapy 8 Paclitaxel 8 Irinotecan 8 Trastuzumab 7 Pemetrexed 6 Carboplatin 6 130-nm albumin-bound paclitaxel 6 durvalumab 5 cemiplimab 5 Erlotinib Hydrochloride 5 Sunitinib 4 Ramucirumab 4 Metformin 4 Gefitinib 4 trastuzumab deruxtecan 3 tislelizumab 3 cabozantinib 3 atezolizumab 3 Taxes 3 Sorafenib 3 Panitumumab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01682772 2019-08-15

TOPARP

Institute of Cancer Research, United Kingdom

Phase 2 Unknown

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡